Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma
Omid Hamid(Angeles Clinic and Research Institute), Giuseppe Gullo(Regeneron (United States)), Inderjit Mehmi, Laura K. Brennan(Regeneron (United States)), John M. Kaczmar(MUSC Hollings Cancer Center), Fang Wang(Temple University), Karl D. Lewis(University of Colorado Denver), Kevin B. Kim(The University of Texas MD Anderson Cancer Center), Amy Weise(Henry Ford Hospital), Kyriakos P. Papadopoulos(Texas Oncology), Dae Ho Lee(Asan Medical Center), Israel Lowy(Bristol-Myers Squibb (Germany)), John Crown(Cancer Trials Ireland), Alexander I. Spira(Virginia Cancer Specialists), Mark R. Middleton(University of Oxford), Guilherme Rabinowits(Baptist Hospital of Miami), Sajeve Thomas(Orlando Health), Jayakumar Mani(Regeneron (United States)), Glenn S. Kroog(Regeneron (United States)), Shuquan Chen(Regeneron (United States)), Matthew G. Fury(Memorial Sloan Kettering Cancer Center), Melinda Yushak(Emory University), Sheila Masinde(Regeneron (United States)), Mark Salvati(Regeneron (United States)), Nathalie Fiaschi(Regeneron (United States)), Anne Paccaly(Regeneron (United States)), Fang Fang(Jinshan Hospital of Fudan University), Tae Min Kim(Seoul National University Hospital), Janice M. Mehnert(NYU Langone Health), Meredith McKean(Sarah Cannon), Vladimir Janković(Regeneron (United States)), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics)
Cited by 37
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k